Drug efficacy reprogramming against aggressive human prostate cancer

We enriched for prostate cancer cells by the selection system used in human iPS purification. Gene expression signature-based chemical prediction enabled us to identify candidate drugs for reverting the EOS (early transposon promoter, OCT4 and SOX2 enhancer) signature with chemoresistance into a chemosensitive phenotype.

10

Kosaka T, Nagamatsu G, Saito S, Oya M, Suda T, Horimoto K